4405-33-8

Usage

InChI:InChI=1/C9H13NO2Si/c1-13(2,3)9-6-4-8(5-7-9)10(11)12/h4-7H,1-3H3

Upstream product

• 768-32-1 trimethylphenylsilane 
• 1450-14-2 1,1,1,2,2,2-hexamethyldisilane 
• 122-04-3 4-nitro-benzoyl chloride 
• 100-00-5 4-chlorobenzonitrile 
• 3704-44-7 octamethyltrisilane 
• 586-78-7 para-nitrophenyl bromide 
• 7697-37-2 nitric acid 
• 108-24-7 acetic anhydride 
• 13183-70-5 1,4-bis-(trimethylsilyl)benzene 
• 591-51-5 phenyllithium 
• 636-98-6 p-nitrobenzene iodide 
• 27607-77-8 trimethylsilyl trifluoromethanesulfonate 
• 75-77-4 chloro-trimethyl-silane 

Downstream Products

• 98-95-3 nitrobenzene 
• 350-46-9 4-Fluoronitrobenzene 
• 768-32-1 trimethylphenylsilane 
• 17983-71-0 N-<4-(trimethylsilyl)phenyl>acetamide 
• 33091-15-5 4-nitrophenyl(phenyl)methanol 
• 17889-23-5 4-(trimethylsilyl)aniline 
• 100475-99-8 4-Nitro-1-benzol 
• 1144-74-7 4-nitrobenzophenone 

Relevant academic research and scientific papers

PREPARATION OF SUBSTITUTED BENZOYLTRIMETHYLSILANES BY THE PALLADIUM-CATALYZED SILYLATION OF SUBSTITUTED BENZOYL CHLORIDES WITH HEXAMETHYLDISILANE

A direct preparative route to benzoyltrimethylsilane has been found by the reaction of benzoyl chloride with hexamethyldisilane in the presence of a specified palladium(II) complex as catalyst.

Organoarsenic probes to study proteins by NMR spectroscopy

Arsenical probes enable structural studies of proteins. We report the first organoarsenic probes for nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) spectroscopy to study proteins in solutions. These probes can be attached to ir

Design, Synthesis, and Implementation of Sodium Silylsilanolates as Silyl Transfer Reagents

There is an increasing demand for facile delivery of silyl groups onto organic bioactive molecules. One of the common methods of silylation via a transition-metal-catalyzed coupling reaction employs hydrosilane, disilane, and silylborane as major silicon sources. However, the labile nature of the reagents or harsh reaction conditions sometimes render them inadequate for the purpose. Thus, a more versatile alternative source of silyl groups has been desired. We hereby report a design, synthesis, and implementation of storable sodium silylsilanolates that can be used for the silylation of aryl halides and pseudohalides in the presence of a palladium catalyst. The developed method allows a late-stage functionalization of polyfunctionalized compounds with a variety of silyl groups. Mechanistic studies indicate that (1) a nucleophilic silanolate attacks a palladium center to afford a silylsilanolate-coordinated arylpalladium intermediate and (2) a polymeric cluster of silanolate species assists in the intramolecular migration of silyl groups, which would promote an efficient transmetalation.

Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity

Modification of a HCV NS5A inhibitor, ombitasvir, led to the identification of 10d with improved pan-genotype NS5A inhibition and better pharmacokinetic properties. The key structural changes to ombitasvir include bioisosteric replacement of carbon with silicon atom. Compared with ombitasvir, the activity of anti-HCV genotypes (GT 1 to 6) of 10d is increased to some extent, especially the inhibitory activity against genotype 3a and 6a is increased by more than seven times, and the dog's in vivo pharmacokinetics properties were also superior to ombitasvir. Further drug evaluation showed that 10d was similar to ombitasvir on plasma protein binding and liver distribution profiles, with no cytotoxicity and no inhibitory effect on both CYP 450 and hERG ligand binding. However, permeability assay results indicated that 10d was not the substrate of P-gp or BCRP transporter, which is different from that of ombitasvir. The results of a 14-day repeat-dose toxicity study identified no toxicity with 10d. Our findings in preclinical tests suggest that the silicon-containing compound 10d could be worthy of continued study as a potential drug candidate.

Ipso-Fluorination of aryltrimethylsilanes using xenon difluoride

Reaction of aryltrimethylsilanes with xenon difluoride in C 6F6/Pyrex at room temperature gives aryl fluorides in good yield. The reaction is inhibited when acetonitrile is used as solvent but proceeds well in CFCl3/Pyrex or CH 2Cl2/Pyrex. Pyrex appears to be a very effective heterogeneous catalyst for this ipso-fluorination. The reaction does not proceed in PTFE, quartz, soda glass or glassy-carbon flasks or Pyrex flasks pre-rinsed with 2 M NaOH. Aryltrimethylstannanes and arylboronic acids and their esters do not undergo ipso-fluorination under similar conditions. Plausible mechanisms involving electrophilic addition of polarised xenon difluoride [FXeδ+?F→Pyrex δ-] followed by ligand coupling are discussed.

Nitro-substituted aryl lithium compounds in microreactor synthesis: Switch between kinetic and thermodynamic control

Be quick or take your time, depending on your goal: A microflow method for the generation and transformation of o-, m-, and p-nitro-substituted aryl lithium compounds enabled the selective use of either the kinetically or the thermodynamically preferred intermediate. In the example pictured, a residence time of 0.06 s at -48 °C led to the formation of 1, whereas 2 was obtained exclusively when the residence time was extended to 63 s.

Palladium-catalyzed silylation of aryl chlorides with hexamethyldisilane

A method for the palladium-catalyzed silylation of aryl chlorides has been developed. The method affords desired product in good yield, is tolerant of a variety of functional groups, and provides access to a wide variety of aryltrimethylsilanes from commercially available aryl chlorides. Additionally, a one-pot procedure that converts aryl chlorides into aryl iodides has been developed.

PYRROLE-3-CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF OBESITY

The present invention relates to compounds of Formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Radiosynthesis, Cerebral Distribution, and Binding of -1-(p-Iodophenyl)-3-(1-adamantyl)guanidine, a Ligand for ? Binding Sites

An analog of 1,3-di-o-tolylguanidine (DTG), -labeled 1-(p-iodophenyl)-3-(1-adamantyl)guanidine (PIPAG), was synthesized as a potential ligand for cerebral ? binding sites.Data from in vitro binding experiments and in vivo experiments on brain distribution suggested that PIPAG binds to ? binding sites with high affinity (Kd in low nanomolar range) as determined by Scatchard analysis and relative potencies of ?-specific drugs.Haloperidol had the highest potency to inhibit PIPAG binding.It was followed by DTG, BMY 14802, and (+)-N-allylnormetazocine.Compounds with high affinities for dopamine receptors (but low affinity for ? binding sites), for opioid receptors, for nicotinic acetylcholine receptors, and for phencyclidine receptors were ineffective inhibitors of PIPAG binding.

Silylative Decarbonylation: A New Route to Arylsilanes

A new synthetic procedure for the preparation of aromatic chlorosilanes via the palladium-catalyzed reaction of methylchlorodisilanes and aromatic acid chloride is described.The silylative decarbonylation process is solventless, can utilize low metal catalyst loadings (500-1000 ppm Pd), is carried out under moderate conditions (145 deg C), and selectively gives aromatic chlorosilanes in good yield, generally 60-85percent.The procedure is tolerant of a variety of aromatic substituents, for example, alkyl, halo, nitro, cyano, imide, acid anhydride, etc., and the synthesis ofseveral new substituted aromatic chlorosilanes containing benzoyl chloride and phthalic anhydride moieties is described.Chloromethyldisilane starting reagents are available from the direct reaction of methyl chloride and silicon, making this methodology an attractive synthetic route to functionalized aromatic chlorosilanes.